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Mucins are members of an expanding family of large multifunctional glycoproteins. Pancreatic mucins have important biological
functions, including the protection, lubrication, and moisturisation of the surfaces of epithelial tissues lining ductal structures within the
pancreas. Several lines of evidence support the notion that deregulated mucin production is a hallmark of inflammatory and neoplastic
disorders of the pancreas. Herein, we discuss the factors that contribute to the lethality of pancreatic cancer as well as the key role
played by mucins, particularly MUC1 and MUC4, in the development and progression of the disease. Aspects pertaining to the
aberrant expression and glycosylation of mucins are discussed, with special emphasis on their potential impact on the design and
implementation of adequate diagnostic and therapeutic strategies for combating this lethal malignancy.
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Mucins are a large family of glycoproteins that, either directly or
indirectly, act to maintain the integrity, lubricate and protect the
epithelial surfaces within the human body. In general, mucins
exhibit a defined spatial and temporal pattern of expression
throughout the development of an organism (Braga et al, 1992). In
numerous pancreatic pathologic situations, however, their expres-
sion is deregulated, and their aberrant expression is often
associated with a poor prognosis (Braga et al, 1992; Reis et al,
1999; Andrianifahanana et al, 2001). This paper will review the role
played by mucins, particularly MUC1 and MUC4, in the
development and progression of pancreatic cancer (PC) and will
highlight key aspects that may account for the lethality of this
malignancy.
THE MUCIN FAMILY
For long, mucins were known as high molecular weight O-
glycoproteins, secreted by specialised epithelial cells. As main
contributors to the rheologic properties of the mucus, mucins were
thought to have the sole functions of protecting and lubricating
epithelial surfaces. Following the development of molecular
biological methods, however, a wide range of mucin structures
became available and gave rise to a plethora of biochemical
definitions of mucins. As the diversity of mucin structures grew in
importance, a variety of functions were assigned accordingly. At
present, a total of 21 genes have received the appellation MUC:
MUC1-2, MUC3A, MUC3B, MUC4, MUC5AC, MUC5B, MUC6-13,
MUC15-20 (Moniaux et al, 2001; Hollingsworth and Swanson,
2004; Andrianifahanana et al, 2004). In all, 14 of these code for
proteins presenting the five common features of a mucin,
including (I) secretion into the mucus layer, (II) high molecular
weight O-glycoprotein, (III) presence of a tandem repeat array
encoded by a unique and centrally positioned large exon, (IV)
presence of a predicted peptide domain containing a high
percentage of serine and threonine residues, and (V) a complex
pattern of mRNA expression.
The 14 classical mucins can be further grouped into two
subfamilies: secreted and membrane-bound. Typically, secreted
mucins are expressed exclusively by specialised epithelial cells, are
secreted in the mucus, and display a restricted expression pattern
within the human body. Among these, MUC2, MUC5AC, MUC5B,
and MUC6 are expressed in the pancreas either under normal
physiologic or tumoral conditions. These four mucins, referred to
as the gel-forming mucins, have a common architecture with a
high level of similarity to the pro-von Willebrand factor. The
secreted mucins whose genomic sequences have been fully
characterised are known to harbour five D domains, thus called
because of their homology to the D domains of the von Willebrand
factor. The D1, D2, D0, and D3 domains are located in the N-
terminal region and the D4 and CK (Cystine Knot) domains in the
C-terminal region. Moreover, cystein-rich domains (called Cys)
alternate with the tandem repeat sequences in a variable number
depending on the mucin (for a review, see Moniaux et al, 2001).
The gel-forming mucins form intermolecular disulphide-linked
multimers. Mucin subunits initially form homodimers through the
disulphide bonds from their CK domains and subsequently hetero-
oligomerise through the D domains from their N-terminal
extremities (Van Klinken et al, 1998). The Cys domains are
believed to bring another level of complexity to the oligomerisa-
tion process via intermolecular disulphide bond formation. As
the composition of gel-forming mucins differs among tissues
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properties of the mucus will be different and specific.
The membrane-bound mucins are composed of MUC1, MUC3A,
MUC3B, MUC4, MUC11, MUC12, MUC16, and MUC17. For the
purpose of clarity, MUC11 and MUC12 will be hereon referred to
as MUC11-12, and MUC3A and MUC3B as MUC3A-B. It is not
fully understood at this point whether these genes are related to
unique or independent loci. The membrane-bound mucins share a
common property of being expressed by distinct cellular types,
epithelial or other. Implanted at the apical surface of epithelial
cells, they are also secreted and, therefore, take part in mucus
formation. As compared to the secreted mucins, they present a
wider and more complex expression pattern. Indeed, they can be
expressed in four distinct forms: membrane-anchored, soluble
(proteolytic cleavage of the membrane-bound form), secreted
(alternatively spliced variants), and lacking the tandem repeat
array (alternatively spliced variants) (Wreschner et al, 1990;
Choudhury et al, 2000; Moniaux et al, 2000). The ratio of one form
to another appears to be tissue-specific and associated to the
physiologic conditions (normal or tumoral). In addition to the
proteolytic cleavage that releases the secreted forms from the cell
surface, mucin precursors from this group, MUC1 and MUC4,
possess a second proteolytic cleavage site that processes the
precursor into a mature heterodimer. This second cleavage is
thought to confer upon mucins their functional conformation.
Membrane-anchored mucins contain a SEA (Sea urchin sperm
protein, Enterokinase and Agrin) module, with the exception of
MUC4. MUC3A-B, MUC4, MUC11-12, and MUC17 contain two to
three epidermal growth factor (EGF)-like domains.
Among the membrane-bound mucins, MUC1 and MUC4 are the
two main mucins associated with PC. Although they both belong to
the same mucin subfamily, MUC1 and MUC4 present significantly
distinct structures. MUC1 has an apparent simple architecture. The
MUC1 gene (Figure 1A) codes for a membrane-associated protein
with distinct domains: an amino-terminal domain consisting of a
20-amino-acid signal peptide and degenerate tandem repeats; a
large central domain (two-thirds of the core protein sequence)
made up of variable numbers of a 20-amino acid repeat; and a
carboxyl terminus made of degenerate tandem repeats, a hydro-
phobic membrane-spanning domain of 31 amino acids, and a
cytoplasmic domain of 69 amino acids. In normal individuals,
there is a variation in the number of repeats per allele (from 25 to
4125 repeats), implying that the length of the repetitive array may
not be critical for the normal function of MUC1. MUC4, on the
other hand, is one of the largest human membrane-anchored
mucins identified to date (Figure 1A). The amino-terminus of
MUC4 is comprised of a 27-residue signal peptide, followed by
three imperfect repetitions of a motif, varying from 126 to 130
residues and by a unique sequence of 554 residues. The central and
largest domain is comprised of a perfect tandem repetition of a 16-
amino-acid residue motif that could be repeated up to 400 times.
Over 20 distinct alleles have been identified for MUC4. These show
a variation in the size (6.5–19kb) of the tandem repeat array. It is
not as yet clear whether the size of the tandem repeat is important
for the functions or expression of MUC4. The C-terminal region
can be divided into 12 domains (CT1 to CT12). CT6, CT7, and CT9
are EGF-like domains, and CT11 corresponds to the transmem-
brane domain. A putative proteolytic cleavage site (a GDPH motif)
is found between domains CT4 and CT5. A MUC4 precursor of
930kDa yields at least two subunits (MUC4a and MUC4b)
following proteolytic cleavage. Hence, MUC4 is predicted to be a
membrane-associated mucin that extends up to 2.12mm above the
cell surface. MUC4a is an extracellular mucin-type glycoprotein
subunit, whereas MUC4b is a growth factor-like transmembrane
subunit (Moniaux et al, 1999). Both the MUC1 and MUC4 genes
encode numerous alternatively splice forms, some of which are
variants devoid of the mucin hallmark, the tandem repeat array.
These splice forms, called MUC1/Y, MUC1/X, MUC1/Z, MUC4/X,
and MUC4/Y, present a growth factor-like architecture and are
thought to be involved in fetal and tumour development. However,
the lack of specific antibodies makes it difficult to perform
appropriate functional studies.
ABNORMAL EXPRESSION OF MUCIN GENES IN PC
Of particular interest, the pattern of mucin expression within the
pancreas varies depending on the pathophysiologic conditions
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Figure 1 (A) Schematic representation of the deduced amino-acid
sequence of the MUC1, MUC2, and MUC4 genes, which are deregulated
in PC. The MUC1 apomucin has an apparent simple structure with a central
domain composed of sequences repeated in tandem, a transmembrane
sequence, and a cytoplasmic tail. MUC4 is a heterodimeric protein,
composed of an 850-kDa mucin-type a subunit, noncovalently linked to an
80-kDa growth-factor-like membrane-bound b subunit. MUC2 is a
secreted mucin with several domains similar to the von Willebrand factor.
Keys to figure: black, signal peptide; vertical lines, tandem repeat; diagonal
lines serine, threonine-rich nonrepetitive sequence domain; dense dots,
domain rich in N-glycosylation sites; open box, unique sequence; hatched
boxes, cystein-rich domain; hatched ovals, EGF-like domain; light grey,
transmembrane domain; small dots, cytoplasmic tail; descending hatched
lines, D domains; ascending hatched lines, CK domain; horizontal lines, C
domain; dense vertical lines, B domain. (B) Schematic representation of the
PanIN lesions and MUC1, 2, and 4 expression during the progression of PC.
Pancreatic intraepithelial neoplasias are thought to mimic the development
of PC, evolving from PanIN-1A (flat epithelial lesions composed of tall
columnar cells with basally located nuclei) to PanIN-3 (papillary lesion with
budding off of small clusters of epithelial cells into the lumen). (C)
Expression of MUC1, MUC2, and MUC4 in IPMT.
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tissue is MUC6 (Kim et al, 2002). MUC6 and MUC1 are already
expressed at an early stage of gestation in the fetal pancreas (Reid
and Harris, 1998; Buisine et al, 2000; Adsay et al, 2002). MUC5B is
moderately expressed, while MUC1 and MUC5AC are weakly
detected in the adult pancreas (Yonezawa et al, 1997; Yonezawa
et al, 1999; Andrianifahanana et al, 2001; Terris et al, 2002). We
have previously reported that the overexpression of the MUC1
gene as well as the aberrant expression of MUC4 were associated
with the development and progression of PC (Swartz et al, 2002;
Park et al, 2003). In the normal pancreas, the expression of MUC1
is confined to the apical membrane of the intralobular ductules. It
is neither expressed in the larger ducts nor in the islet of
langerhans. The overexpression of MUC1 is observed during the
early stages of the development of PC, which is further increased in
invasive carcinoma (Levi et al, 2004). On the other hand, MUC4 is
minimally or not expressed in the normal pancreas or chronic
pancreatitis but is highly expressed in human pancreatic tumours
and pancreatic tumour cell lines (Balague et al, 1994; Choudhury
et al, 2000; Andrianifahanana et al, 2001).
Lesions known as pancreatic intraepithelial neoplasia (PanIN)
are thought to represent the early stages of PC development
(Figure 1B). They progress from flat to papillary without atypia, to
papillary with atypia, and to lesions with severe atypia and are
classified PanIN-1A to PanIN-1B, PanIN-2, and PanIN-3 (Hruban
et al, 2001). Atypical intraductal lesions can progress to invasive
adenocarcinoma (Brat et al, 1998). MUC4 is expressed by
metasplastic ducts and its expression increases with a higher
grade of PanINs (Swartz et al, 2002; Park et al, 2003). Similarly,
MUC1 expression also increases with the progression of PanIN
lesions (Figure 1B), whereas MUC2 expression remains unchanged
(Adsay et al, 2002).
MUC gene expression has not been extensively studied in
intraductal papillary-mucinous tumours (IPMTs) of the pancreas.
MUC2 and MUC5AC levels were shown to be very high in IPMT
compared to adenocarcinomas (Terada and Nakanuma, 1996;
Yonezawa et al, 1997). An altered expression of MUC genes
(overexpression of MUC2 and MUC5AC) was seen in IPMTs, which
could be correlated with types and lesions (Figure 1C) (Terris et al,
2002). The main difference between adenocarcinoma of the
pancreas and IPMT is an increased expression of MUC2 associated
with a decreased expression of MUC1 in IPMT vs adenocarcinoma.
(Adsay et al, 2002) In both cases, MUC4 is highly aberrantly
expressed. While mucin gene profile is in general a good marker for
PC, it also serves to distinguish IPMT from adenocarcinoma.
Other mucin genes, such as MUC11 (Williams et al, 1999),
MUC12 (Williams et al, 1999), and MUC17 (Gum, Jr et al, 2002) are
detected in pancreatic tissues. However, their specific expression
pattern in relation to PC development is still unclear.
MUCINS FOR PC DIAGNOSTIC
The pancreas is the second largest gland of the digestive system
following the liver. It lies retroperitoneally in the upper abdominal
cavity, with its head enclosed by the curve of the duodenum and its
tail reaching to the spleen. It performs both endocrine and
exocrine functions. The exocrine component, constituting about
95% of the mature pancreas, is made up of 85% acinar cells and
10% of secreting ductal cells. The endocrine cells are believed to
occupy just 1–2% of the total pancreatic volume in adults.
Adenocarcinomas of the ductal phenotype constitute over 85%
of PC, and other tumours of ductal type, such as mucinous cystic
tumours, serous cystic tumours and IPMTs make up another 5–
7%. A number of factors, including hereditary, environmental,
occupation, and social factors are now recognised as potential
contributors to the development of PC (Michaud et al, 2003).
Pancreatic cancer is an international problem because of its
increasing incidence worldwide. The incidence and age-adjusted
mortality rates are almost equal, underscoring the aggressive
nature of the disease. It is a daunting challenge for modern
medicine as the survival rates for patients diagnosed with
metastatic PC range from 4 to 6 months on average. The lethality
of the disease is best illustrated by its poor 5-year survival rate of a
mere 5%. The highest cure rate only occurs if the tumour is truly
localised to the pancreas; however, this stage of disease accounts
for fewer than 20% of all cases. For those patients with localised
disease and small tumour size (o2cm) with no lymph node
metastases and no extension beyond the ‘capsule’ of the pancreas,
complete surgical resection can yield actuarial 5-year survival rates
of 18–24% (Yeo et al, 1997, 1999). Unfortunately, the signs of early
stage PC are vague and often attributed to other problems by both
patients and physicians. More specific symptoms tend to develop
after the tumour has grown to invade other organs or blocked the
bile ducts. Patients are usually diagnosed at an advanced stage,
with a high incidence of associated metastases, spread all over the
body. The inability to diagnose PC at an early, localized, and
curable stage has contributed to poor prognosis. The silent course
of PC and its explosive fatal outcome have hindered studies of
identification of early biochemical and genetic alterations that
could help us diagnose the disease at a curable stage and develop
successful therapeutic strategies. Thus, PC remains a dismal
disease and early diagnostic markers and therapeutic targets are
urgently needed.
Early symptoms of PC are difficult to detect and are often
ignored. There are no tumour-specific markers for PC; markers
such as serum CA 19-9, DUPAN-2, and CA125 that are being used
as potential targets have low specificity (McLaughlin et al, 1999;
Rhodes, 1999). For over two decades, the structures of these
antigens (CA 19-9, DUPAN2, or CA 125) have been heavily
Table 1 Mucin gene expression in different pancreatic physiologic conditions
Adenocarcinoma
Gene Fetus Normal pancreas Pancreatitis IPMT PanIN Tissue Cell line
MUC1  /+ + ++ + ++ +++ +++
MUC2      +++      /++
MUC3   77 7 ND 7  /+
MUC4      ++ + to +++ +++ +++
MUC5AC   +  /+ ++ ND  /+  /+
MUC5B   + ++ ++ ND +/++  /++
MUC6 + ++ ++/+++ ++ ND ++/+++  /+++
MUC11/12 ND  /+ ND ND ND ND ND
MUC16 ND ND ND ND ND ++ ND
MUC17 ND ND ND ND ND ND +
 ¼negative; +¼low; ++¼moderate; +++¼intense; ND¼not determined;  /+¼from negative to positive depending the sample; 7¼negative or positive depending the
reports; IPMT¼intraductal papillary-mucinous tumours; PanIN¼pancreatic intraepithelial neoplasias.
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detect early cancers. These antigens contain oligosaccharide
structures that are being recognised by monoclonal antibodies.
Further, these saccharide epitopes are present on the O-glycosidic
chains harboured by the apomucin backbones. For examples,
MUC1 carries CA19-9 (Burdick et al, 1997) and DUPAN-2
(Khorrami et al, 2002) epitopes, and MUC16 carries CA 125
epitope (Yin et al, 2002). At this time, CA19-9 remains the only
Food and Drug Administration (FDA)-approved marker to
monitor PC. The CA 19-9 recognises a mucin-type glycoprotein
sialosyl lewis a/b antigen. Since 5% of the general population are
lewis a/b negative, the maximum sensitivity of this marker is of
95%.
Aberrant glycosylation occurs in essentially all types of
experimental and human cancers and has been associated with
tumorigenecity and metastasis. In fact, many glycosyl epitopes
constitute tumour-associated antigens (TAAs) and have been used
as a target for immunotherapy and diagnosis. The nature of
aberrant glycosylation as a result or a cause of cancer remains
enigmatic. Many recent studies have indicated that some, if not all,
types of aberrant glycosylation are a result of initial oncogenic
transformation, as well as a key event in induction of invasion and
metastasis.
The mucin-type O-glycans are attached to the glycoproteins
through O-glycosidic linkages between N-acetylgalactosamine and
serine or threonine amino-acid residues in the apomucin moieties.
O-glycans are assembled by a series of reactions catalysed by
glycosyltransferases and sulphotransferases in the Golgi compart-
ment. In cancer cells, the expression pattern of these enzymes is
dysregulated and leads to tumour-specific glycanic epitopes.
Depending on the glycosyltransferases expressed, several hundred
different O-glycan structures have been described and classified
according to their core structures. All of the cores have the N-
acetylgalactosamine linked to the serine or threonine residues that
represents the Tn antigen in common. When sialylated, this
antigen forms the sialyl-Tn (sTn) epitope reported to be expressed
on the surface of mucin cores. Indeed, sTn is detected at the
surface of MUC1 overexpressed by pancreatic adenocarcinoma
cells (Burdick et al, 1997). It has been proposed that the
appearance of the sTn antigen might result from MUC1 over-
expression. The abundance of acceptor sites may saturate the post-
translational modification (Burdick et al, 1997). The sTn antigen is
recognised by the mouse monoclonal antibody CC49, which is
being extensively investigated for the development of radio-
immunotherapeutic protocols.
Alternatively, the Tn antigen can be elongated to form one of the
eight distinct cores and terminated with sulphate, sialic acid,
fucose, galactose, N-acetylglucosamine, and N-acetylgalactosa-
mine. Depending on the physiologic conditions, the peripheral
sugar may vary and gives rise to tumor-associated antigens, such
as Le
a (Lewis
a), Le
b,L e
x,L e
y, sLe
a, sLe
c, and sLe
x. The CA 19-9
described previously recognises the sLe
a and DUPAN-2 recognises
the sLe
c.
IMPLICATION OF MUCINS IN THE PATHOGENESIS
OF PC
As described previously, both the glycosylation and the expression
of mucins are deregulated during the development and progres-
sion of pancreatic adenocarcinoma. The main mucins that present
the most deregulated expression patterns are MUC1 and MUC4,
two mucins that belong to the membrane-anchored mucin
subfamily. Therefore, this review will focus on the known
functions of MUC1 and MUC4. Both MUC1 and MUC4 play a
key role in the development of PC as well as in its progression
(invasion and metastasis). As indicated earlier in this paper, the
high incidence of metastases in PC is the major cause of its
lethality. MUC1 and MUC4 are implicated in almost all of the steps
associated with the development of metastases.
MUC1 and MUC4 possess antiadhesive properties. The negative
charge of the O-glycosidic chains carried by their central repetitive
domain provides a extended conformation to MUC1 and MUC4,
with a size up to 500nm and 2.12mm (Moniaux et al, 1999),
respectively. Moreover, MUC1 and MUC4 are not only upregulated
in PC but their upregulation is also accompanied by the loss of
their strictly apical localisation. The steric hindrance caused by the
overexpression of these two extended glycoproteins disturbs the
cell–cell and/or cell–matrix interactions (Komatsu et al, 1997).
This physical mechanism favours the release of cancer cells into
the circulation. MUC1 also interacts directly with b-catenin via an
SXXXXXSSL motif (where X represents any amino-acid residues)
in its cytoplasmic tail (Yamamoto et al, 1997). b-Catenin plays
important functions in the formation of the cell–cell junction via
E-cadherin interaction (Hulsken et al, 1994). b-Catenin also binds
to adenomatous polyposis coli (APC) (partner in the Wingless/
Wnt-1 signal pathway). The Wnt-1 intracellular pathway is directly
implicated in the development of the central nervous system.
Complex binding to b-catenin is a mutually exclusive process. APC
overexpression reduces the level of free cytoplasmic b-catenin, and
thus reduces the formation of b-catenin/E-cadherin complexes and
also decreases intercellular adherence. The formation of these
complexes is regulated by the phosphorylation of the cytoplamic
tail of each partner by GSK3b. After phosphorylation, b-catenin is
degraded. GSK3b is also able to phosphorylate the b-catenin-
binding site on the MUC1 cytoplasmic tail (Li et al, 1998). The
phosphorylation at the serine residue of the cytoplasmic tail of
MUC1 by GSK3b was shown to decrease the binding of MUC1 to b-
catenin (Li et al, 1998). The relative level of MUC1, E-cadherin, b-
catenin, GSK3b, and APC seem to be critical for maintaining
epithelium integrity. The overexpression of MUC1 leads to an
increase in the interaction between MUC1 and b-catenin, thereby
inhibiting b-catenin/E-cadherin interaction and disrupting cell–
cell contacts, which facilitate the release of the tumour cell from
the tissue. The cytoplasmic tail of MUC1 is also phosphorylated at
tyrosine residue. In vitro, tyrosine phosphorylation of the MUC1
cytoplasmic domain increases recolonisation and promotes
changes in cell–cell adhesion (Quin and McGuckin, 2000).
Interestingly, both src and EGFR induce tyrosine phosphorylation
and enhance interactions between MUC1 and b-catenin (Li et al,
2001; Schroeder et al, 2001).
The expression of mucin-associated carbohydrate antigens, sLe
x
and sTn, is associated with higher-grade PanIN lesions (Park et al,
2003) and is thought to result from a shift in the expression of
glycosyltransferases. These mucin-associated antigens are known
to bind endothelial cells through the P- and E-selectins, and the
cell-adhesion molecule, ICAM-1 (Regimbald et al, 1996). The P-
selectin ligand (PSGL-1) (Sako et al, 1993) presents a structure
similar to MUC1 and MUC4 and carries within its repetitive
domain O-glycosidic chains with terminal sugars comparable to
those of MUC1 and MUC4 in tumoral situations. Therefore, in
addition to favouring the release of PC cells, MUC1 and MUC4 also
facilitate their extravasation into and/or from the circulation
(Burdick et al, 1997). MUC4 is known to inhibit tumour killing by
lymphokine-activated killer cells (Komatsu et al, 1999).
Information regarding the role of MUC1 and MUC4 in the
growth of primary pancreatic tumours has remained scarce until
recently. Both mucins have been reported to serve as potential
modulators of the receptor tyrosine kinase signalling pathways.
Indeed, both MUC1 and MUC4 have been referred to as the
heterodimeric partners of EGFR/HER1 (Li et al, 2001; Schroeder
et al, 2001) and HER2 (Carraway et al, 2002), respectively. When
MUC1 interacts with EGFR, the cytoplasmic tail of MUC1 becomes
phosphorylated and leads to the activation of c-Src (Li et al, 2001).
Moreover, the formation of the complex activates the mitogenic
MAP kinase pathway (Schroeder et al, 2001). For MUC4, its
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this growth factor receptor, and in synergy with neuregulin,
potentiates the phopshorylation of HER2 and HER3. Phosphoryla-
tion of HER2 occurs at residue Tyr1248 after binding with MUC4
and leads to the upregulation of the cell-cycle inhibitor, p27
kip
(Jepson et al, 2002). However, in presence of neuregulin, MUC4/
HER2 activation downregulates p27
kip but activates the protein
kinase B/Akt via HER3. Therefore, MUC4 appears to be a
modulator of cell proliferation. Inhibition of MUC4 expression
using antisense or short-interfering RNA (siRNA) oligonucleotides
specific to MUC4 results in a decreased tumorigenicity and
dissemination of cancer cells (Singh et al, 2004). We believe that
MUC4 is implicated in tumour growth and metastasis by directly
altering the tumour cell properties (adhesion/aggregation and
motility), and/or in part, via modulating HER2 expression.
CONCLUSIONS AND PERSPECTIVES
Pancreatic cancer is an international problem because of its
increasing incidence worldwide. The incidence and age-adjusted
mortality rates are almost equal, underscoring the aggressive
nature of the disease. Although efforts are being made to unveil the
principles governing the initiation and progression of this cancer,
and to identify the factors that confer its particular aggressiveness,
the exact succession of molecular events underlying the develop-
ment of this devastating malignancy has remained unsolved. The
management of PC is, therefore, an ongoing challenge. Mucins
have been implicated in the pathogenesis and progression of PC.
Differential glycosylation, aberrant expression, and alternative
splicing of mucins are being investigated in PC. MUC1 and
MUC4 are finding unique functions in the early diagnosis and
progression of the disease. The potential use of these mucins in the
targeted therapy of pancreatic and other cancers is under active
investigation.
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